On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. , holding that Amarin failed to plausibly allege that Hikma…
On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., holding that Amarin failed to plausibly allege that Hikma actively induced infringement under 35 U.S.C. § 271(b). The ruling marks a significant development in pharmaceutical patent litigation and clarifies the threshold that branded drug manufacturers must satisfy when pursuing inducement theories against generic competitors.
At the heart of the dispute was whether Hikma's marketing and labeling of its generic product could give rise to liability for induced infringement of Amarin's method-of-use patents. The Court rejected Amarin's allegations as insufficient, emphasizing that the inducement inquiry turns on whether the defendant affirmatively encouraged an infringing use. Mere knowledge that infringement could occur, or foreseeability that some end users might use the product in an infringing manner, does not meet the statutory standard. Plaintiffs must instead identify specific conduct by the defendant that actively promotes or instructs others to engage in the patented use.
The decision provides meaningful protection for generic manufacturers that rely on FDA-approved skinny labels, a regulatory mechanism that permits generics to carve out patented indications from their labeling. By reinforcing that a properly carved-out label, standing alone, does not constitute active encouragement of infringement, the Court has preserved a critical pathway for generic entry into markets where some indications remain under patent protection. This outcome should ease longstanding concerns within the generic industry that inducement claims could effectively nullify the benefits of the skinny label framework.
For branded pharmaceutical companies, the ruling raises the bar at the pleading stage. Complaints alleging induced infringement will now need to articulate concrete facts showing affirmative steps by the generic to encourage infringing use, rather than relying on general allegations of awareness or market dynamics. Companies should also revisit their litigation strategies and consider how product communications, promotional materials, and labeling decisions may be characterized under this clarified standard.
This alert is intended for general informational purposes only and does not constitute legal advice. Clients facing matters involving pharmaceutical patent litigation or induced infringement questions should consult counsel for guidance tailored to their specific circumstances.